Influence of Age on the Absorption and Metabolism of Cocoa Flavanols

NCT ID: NCT01790009

Last Updated: 2013-02-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Accumulating evidence suggests that regular consumption of foods and beverages rich in flavanols, such as cocoa, tea, apples and wine, may have cardiovascular benefits. Several well-controlled randomised human intervention studies have shown that cocoa flavanols have beneficial effects on blood pressure, endothelial function and other biomarkers of cardiovascular health. These vascular improvements have been correlated in time with changes in plasma flavanol metabolites. The health benefits of flavanol consumption are therefore likely dependent on changes in their absorption, distribution, metabolism and excretion (ADME). Recent studies have provided detailed information regarding the absorption and metabolism of cocoa flavanols. However, there is a lack of information on whether there are changes in flavanol absorption and metabolism with increasing age.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Flavanol Rich drink

Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)

Group Type ACTIVE_COMPARATOR

Flavanol rich drink

Intervention Type DIETARY_SUPPLEMENT

Flavanol rich drink

Flavanol Intervention drink 400 mg/75 Kg BW

Group Type ACTIVE_COMPARATOR

Flavanol rich drink

Intervention Type DIETARY_SUPPLEMENT

Acetaminophen

2 tabletsx500 mg

Group Type ACTIVE_COMPARATOR

Acetaminophen

Intervention Type DRUG

2x500 mg Acetaminophen

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flavanol rich drink

Intervention Type DIETARY_SUPPLEMENT

Acetaminophen

2x500 mg Acetaminophen

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Comparison of two different doses of a flavanol rich drink Paracetamol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* signed consent form
* Caucasian
* Good general health
* No allergy to milk products or sensitivity to alkaloids/caffeine,
* No gastrointestinal disorders (e.g., chronic constipation, diarrhoea, inflammatory bowel disease, irritable bowel syndrome, or other chronic gastrointestinal complaints)
* Not diabetic or suffering from hypertension (140/90 mm Hg),
* No anaemia or gall bladder problems.

Exclusion Criteria

* those on a weight reducing dietary regimen
* Taking any dietary supplements
* Consuming more than 15 units (120g) of alcohol per week
* Taking anti-inflammatory medication
* Smokers
* Those with sensitivities to chocolate, reduced calorie sweeteners, dairy, nuts or gluten,
* Vegetarians or vegans.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Reading

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeremy Paul Edward Spencer

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeremy Spencer, PhD

Role: STUDY_DIRECTOR

University of Reading

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Food and Nutritional Sciences

Reading, Berkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FLAV-AGE01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.